as 03-28-2025 4:00pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 506.1M | IPO Year: | 2021 |
Target Price: | $32.86 | AVG Volume (30 days): | 411.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.11 | EPS Growth: | N/A |
52 Week Low/High: | $7.90 - $30.19 | Next Earning Date: | 05-14-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 278.37% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Jones Jeffrey Alan | CGEM | Chief Medical Officer | Feb 25 '25 | Sell | $8.53 | 4,895 | $41,754.35 | 174,164 | |
SUMER JACQUELYN L | CGEM | Chief Legal Officer | Feb 25 '25 | Sell | $8.53 | 3,756 | $32,038.68 | 136,895 | |
AHMED NADIM | CGEM | President and CEO | Feb 25 '25 | Sell | $8.53 | 12,529 | $106,872.37 | 430,621 | |
Michaelson Jennifer | CGEM | Chief Scientific Officer | Jan 6 '25 | Sell | $12.51 | 4,000 | $50,040.00 | 95,760 |
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
PR Newswire
2 months ago
GlobeNewswire
4 months ago
GlobeNewswire
5 months ago
GlobeNewswire
5 months ago
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.